KYTX
Income statement / Annual
Last year (2023), Kyverna Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Kyverna Therapeutics, Inc.'s net income was -$60.37 M.
See Kyverna Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
Operating Revenue |
$0.00 |
$7.03 M |
$5.66 M |
Cost of Revenue |
$1.71 M
|
$1.05 M
|
$586,000.00
|
Gross Profit |
-$1.71 M
|
$5.97 M
|
$5.07 M
|
Gross Profit Ratio |
0
|
0.85
|
0.9
|
Research and Development Expenses |
$49.92 M
|
$28.40 M
|
$25.85 M
|
General & Administrative Expenses |
$12.48 M
|
$8.01 M
|
$6.15 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$12.48 M
|
$8.01 M
|
$6.15 M
|
Other Expenses |
-$55,000.00
|
-$9,000.00
|
-$2,000.00
|
Operating Expenses |
$62.41 M
|
$36.41 M
|
$32.00 M
|
Cost And Expenses |
$62.41 M
|
$36.41 M
|
$32.00 M
|
Interest Income |
$2.28 M
|
$565,000.00
|
$1,000.00
|
Interest Expense |
$187,000.00
|
$65,000.00
|
$3,000.00
|
Depreciation & Amortization |
$1.71 M
|
$1.05 M
|
$586,000.00
|
EBITDA |
-$58.47 M |
-$27.78 M |
-$25.76 M |
EBITDA Ratio |
0
|
-3.95
|
-4.55
|
Operating Income Ratio |
0
|
-4.18
|
-4.66
|
Total Other Income/Expenses Net |
$2.04 M
|
$491,000.00
|
-$4,000.00
|
Income Before Tax |
-$60.37 M
|
-$28.89 M
|
-$26.35 M
|
Income Before Tax Ratio |
0
|
-4.11
|
-4.66
|
Income Tax Expense |
$0.00
|
$56,000.00
|
$1,000.00
|
Net Income |
-$60.37 M
|
-$28.89 M
|
-$26.35 M
|
Net Income Ratio |
0
|
-4.11
|
-4.66
|
EPS |
-0.0001 |
-1.12 |
-1.02 |
EPS Diluted |
-0.0001 |
-1.12 |
-1.02 |
Weighted Average Shares Out |
$673.62 M
|
$25.80 M
|
$25.80 M
|
Weighted Average Shares Out Diluted |
$673.62 M
|
$25.80 M
|
$25.80 M
|
Link |
|
|
|